Nevolat (Liraglutide)

Liraglutide, the active ingredient in Nevolat, is a GLP‑1 receptor agonist presented as a subcutaneous injectable for subcutaneous use. It is indicated for the management of type 2 diabetes mellitus and for chronic weight management in adults with obesity. The medication works by enhancing glucose‑dependent insulin secretion and reducing appetite.

GNH USA supplies Nevolat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures product integrity and regulatory compliance across EU and global markets.

Nevolat is a GLP‑1 receptor agonist used in metabolic disease management, targeting glucose regulation and body weight.

Type 2 diabetes mellitus: improves glycaemic control by increasing insulin secretion and lowering glucagon levels. Obesity: promotes weight loss through appetite suppression and delayed gastric emptying. Cardiovascular risk reduction: lowers incidence of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Common Side Effects: - Nausea: mild to moderate, often transient. - Vomiting: may accompany nausea. - Diarrhoea: occasional, usually resolves. - Constipation: less frequent. - Headache: mild. - Injection site reactions: redness or swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Gallbladder disease: cholelithiasis or cholecystitis. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Thyroid C‑cell tumours: risk observed in rodent studies. - Acute kidney injury: rare, may follow severe gastrointestinal loss. - Anaphylaxis: rare allergic reaction.

Before initiating Nevolat, consider the following precautions: - Renal function: assess baseline and monitor periodically. - Pancreatitis: discontinue if signs of acute pancreatitis appear. - Thyroid disease: avoid in patients with a personal or family history of medullary thyroid carcinoma or MEN2. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Drug interactions: review concomitant medications for hypoglycaemia risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nevolat may interact with several drug classes.

Major Interactions (Avoid): - Insulin: increased risk of severe hypoglycaemia. - Sulfonylureas: heightened hypoglycaemia potential. - Medications causing gastrointestinal irritation: may exacerbate nausea.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR values. - Beta‑blockers: may mask hypoglycaemia symptoms. - Oral contraceptives: potential reduced efficacy.